StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) stock

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Earnings

Provectus Biopharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Provectus Biopharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2016ended Sep 30, 2016Nov 10, 2016after the close–––Filing
Q2 FY2016ended Jun 30, 2016Aug 9, 2016after the close–––Filing
Q3 FY2015ended Sep 30, 2015Nov 5, 2015before the open–––Filing
Q2 FY2015ended Jun 30, 2015Aug 6, 2015before the open–––Filing
Q1 FY2015ended Mar 31, 2015May 7, 2015before the open–––Filing
Q4 FY2014ended Dec 31, 2014Mar 12, 2015before the open–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Provectus Biopharmaceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Provectus Biopharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Provectus Biopharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?